ArticleBritish journal of clinical pharmacology2026
Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.European journal of clinical pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimMetabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta-analysis (NMA) systematically reviews and compares the efficacy and safety of glucagon-like peptide-1 receptor agonists, tirzepatide and sodium-glucose co-transporter-2 inhibitors for this condition. The results of the SLR and NMA were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
methodsThe MEDLINE and EMBASE databases, as well as the Cochrane Central Register of Controlled Trials, were systematically searched for publications from database inception to 9 November 2024. Risk of bias assessment of the included randomized clinical trials was performed using the Cochrane Risk of Bias 2 tool. Effect sizes were synthesized using pairwise and NMAs within a random-effects framework, assessing heterogeneity and estimating treatment rankings via the surface under the cumulative ranking curve. Analyses were performed using R software with the 'netmeta' package.
resultsOverall, 25 studies involving 2688 participants were included in the analysis. Exenatide and tirzepatide significantly reduced liver fat fraction and liver enzymes vs. placebo, outperforming liraglutide and other agents. Liraglutide and dapagliflozin improved hepatic steatosis by controlled attenuation parameter, whereas empagliflozin reduced proton density fat fraction dose-dependently.
conclusionThis NMA demonstrated that GLP-1 RAs, SGLT-2 inhibitors and tirzepatide significantly improve surrogate markers of NAFLD, with exenatide and tirzepatide showing the greatest efficacy in reducing hepatic steatosis. PROSPERO ID CRD42024609736.
Indexed as
Identifiers
41703425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.